Check out this Bloomberg Law article where DrugPatentWatch shows how the number of patent challenges is increasing, while the number of challengers of each patent is also increasing. Why might this…
Check out the latest issue of Lab Manager where I discuss my interest in informatics, the complexities of informatics for today’s scientists, and some of the tools available. https://www.labmanager.com/ask-the-expert/trends-in-informatics-22895
In response to customer requests, we’ve built some new tools for formulary management. You can preview these tools at: Recent Generic Drug Launches Upcoming 180-Day Patent Challenge Exclusivity Expirations Anticipate…
Let DrugPatentWatch build custom dashboards and reports to take the load off of your team. We can ensure the production of accurate, objective, and timely intelligence to help you quickly…
Drug repurposing patent documents vs peer review: patent information comes more than 600 days earlier on average
0
This article was originally published by Hermann Mucke & Peter Mucke in Future Drug Discovery under a Attribution-NonCommercial-NoDerivatives 4.0 Unported License. https://doi.org/10.4155/fdd-2020-0001. Drug developers require access to scientific information in…
In a recent court ruling, the U.S. Court of Appeals for the Federal Circuit (CAFC) denied a petition to rehear arguments regarding the invalidity of patent claims containing the phrase…
One of our clients, the Belarus Republican Scientific and Technical Library recently posted an article on how they support innovation. They open with the statement that “The novelty, effectiveness and…
Here’s a copy of the recent talk on Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition. It’s based on the book Make Better Decisions, which distills insights…
DrugPatentWatch was used in a recent research study on branded drug sales following generic entry. In this paper, authors Jeffrey Fujimoto, Daniel M Tien, Sophie Snyder, Jeppe A Hertz, and…
DrugPatentWatch serves companies across the drug development-delivery sector. A common request among drug manufacturers, payers, and suppliers alike is anticipation of which branded drugs will face generic competition, and when…
